Developing of an Integrative Medicine Inpatient Care Program for Breast Cancer Patients Post-Chemotherapy

Adjuvant chemotherapy for breast cancer (BC) has improved survival rates but often causes adverse effects such as nausea, vomiting, myelosuppression, and peripheral neuropathy, which can greatly impact patient quality of life. Integrative medicine (IM) provides adjunctive therapies to alleviate these toxicities and support immune function, yet existing clinical practice guidelines and pathways offer broad recommendations that may not sufficiently address the specific needs of post-chemotherapy BC patients. To address this gap, we developed an IM Inpatient Care Program framework for BC patients within one week of chemotherapy administration, drawing on the Korean Medicine Clinical Practice Guideline (KMCPG) for BC supportive care, an established clinical pathway, and additional guidelines focused on chemotherapy-related toxicities. The proposed inpatient model prioritizes systematic monitoring, early detection, and management of common chemotherapy-induced side effects such as neutropenia, peripheral neuropathy, gastrointestinal issues, and psychological distress. Key components include vital sign surveillance, targeted diagnostic tests (e.g., hematology, imaging), dietary and lifestyle recommendations, tailored herbal medicine prescriptions, acupuncture, moxibustion, and referral protocols for serious complications. The IM Inpatient Care Program aims to standardize treatment processes, enhance patient and clinician satisfaction, and reduce potential emergency department visits. By aligning evidence-based guidelines with real-world clinical insights, this model provides a structured approach to optimize BC patient care post-chemotherapy. Future efforts should involve implementing and evaluating the program in diverse clinical settings to refine its utility, measure outcomes, and potentially lower healthcare costs while improving quality of life for BC patients.